Viking Therapeutics/$VKTX
Viking Therapeutics shares are trading lower as concerns about its speculative nature and reliance on successful Phase III trial results for its obesity drug pipeline weigh on investor sentiment.
1 hour ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
46
ISIN
US92686J1060
Website
VKTX Metrics
BasicAdvanced
$3.2B
-
-$1.15
0.83
-
Price and volume
Market cap
$3.2B
Beta
0.83
52-week high
$74.15
52-week low
$18.92
Average daily volume
3.5M
Financial strength
Current ratio
44.246
Quick ratio
43.522
Long term debt to equity
0.059
Total debt to equity
0.118
Interest coverage (TTM)
-1,914.63%
Management effectiveness
Return on assets (TTM)
-11.74%
Return on equity (TTM)
-14.40%
Valuation
Price to book
3.73
Price to tangible book (TTM)
3.73
Price to free cash flow (TTM)
-23.369
Growth
Earnings per share change (TTM)
23.83%
3-year earnings per share growth (CAGR)
16.19%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $3.2B as of May 30, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of May 30, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.